Stock FOLD AMICUS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Amicus Therapeutics, Inc.

Equities

FOLD

US03152W1099

Market Closed - Nasdaq
Other stock markets
 21:00:00 01/05/2024 BST 		5-day change 1st Jan Change
10.43 USD +4.40% Intraday chart for Amicus Therapeutics, Inc. -2.61% -26.50%
03-18 JPMorgan Adjusts Price Target on Amicus Therapeutics to $19 From $21, Maintains Overweight Rating MT
03-05 Amicus Therapeutics Insider Sold Shares Worth $389,543, According to a Recent SEC Filing MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Amicus Therapeutics Insider Sold Shares Worth $389,543, According to a Recent SEC Filing
Amicus Therapeutics Swings to Q4 Earnings, Revenue Rises
Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2024
Amicus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Amicus Therapeutics Insider Sold Shares Worth $390,018, According to a Recent SEC Filing
Amicus Therapeutics Insider Sold Shares Worth $683,958, According to a Recent SEC Filing
Amicus Therapeutics Insider Sold Shares Worth $404,106, According to a Recent SEC Filing
Amicus Therapeutics Insider Sold Shares Worth $934,659, According to a Recent SEC Filing
Amicus Therapeutics Insider Sold Shares Worth $449,545, According to a Recent SEC Filing
Amicus Therapeutics Sees Revenue Growth of 21% in 2023
Amicus Therapeutics, Inc. Provides Revenue Guidance for the Year 2024
Amicus Therapeutics Insider Sold Shares Worth $734,007, According to a Recent SEC Filing
Amicus Therapeutics Insider Sold Shares Worth $490,411, According to a Recent SEC Filing
Amicus Therapeutics Insider Sold Shares Worth $253,542, According to a Recent SEC Filing
Amicus Therapeutics Shares Climb After Morgan Stanley Upgrade
Amicus Therapeutics Insider Sold Shares Worth $129,693, According to a Recent SEC Filing
Amicus Therapeutics Announces Executive Changes
Amicus Therapeutics' Q3 Net Loss Narrows, Revenue Rises
Amicus Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Amicus Therapeutics Insider Sold Shares Worth $131,489, According to a Recent SEC Filing
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FOLD Stock
  4. News Amicus Therapeutics, Inc.
  5. Other languages